Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review
- PMID: 37842458
- PMCID: PMC10571068
- DOI: 10.7759/cureus.45150
Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review
Abstract
Stent thrombosis (ST) is a rare but catastrophic event to happen to a stented coronary artery. The incidence of ST has greatly been reduced after the advent of modern drug-eluting stent (DES) implants, which have become the most preferred treatment option in the stenting category for coronary artery disease (CAD). Although the risk reduction by newer category implant provides substantial benefits, the possibility of thrombosis still exists mostly during the early stage of DES implantation. The development of ST after percutaneous coronary intervention (PCI) can be predicted by multiple factors, but advancements in early diagnostic techniques and modified stent types have greatly reduced the occurrence of this complication. Mortality, which is one of the complications of ST, is primarily influenced by patient-related factors such as incomplete treatment duration of dual antiplatelet therapy (DAPT). The duration of DAPT after DES implantation in patients with acute coronary syndrome (ACS) is determined based on individual characteristics, mainly considered in view of bleeding or ischemia risk. Risk evaluation systems like DAPT/precise-DAPT scores help tailor and personalize the duration of DAPT for each individual patient. This systematic review contains pertinent articles extracted from the PubMed database. We retrieved articles from various study categories, encompassing publications from the period spanning 2014 to 2022. Our analysis highlighted results from studies investigating different aspects contributing to ST development. The most favorable prevention option was the use of customized DAPT intervention based on patient-specific predictable factors. Several complications associated with ST were identified, including recurrent ST, major adverse cardiovascular events (MACE) encompassing all-cause mortality (including cardiac and non-cardiac mortality), cerebrovascular accidents (CVA) or transient ischemic attacks (TIA), hospitalization due to heart failure, and myocardial infarction requiring revascularization. Mortality was also observed as a significant outcome. The umbrella term of ST includes multiple causative factors. Although DES has improved patient survival rates vastly with its usage, careful risk factor assessment and required follow-up, in each individual being stented, further guarantee a more promising reduction in late adverse outcomes.
Keywords: coronary artery disease (cad); drug eluting stents (des); dual-antiplatelet therapy (dapt); post pci; stent thrombos.
Copyright © 2023, Sohail et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents.JACC Asia. 2021 Nov 23;1(3):345-356. doi: 10.1016/j.jacasi.2021.08.010. eCollection 2021 Dec. JACC Asia. 2021. PMID: 36341224 Free PMC article.
-
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20. Am Heart J. 2021. PMID: 33621541
-
The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.Int J Cardiol. 2017 May 15;235:73-86. doi: 10.1016/j.ijcard.2017.02.091. Epub 2017 Feb 24. Int J Cardiol. 2017. PMID: 28284499
-
Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.J Thromb Thrombolysis. 2020 Aug;50(2):337-354. doi: 10.1007/s11239-019-02033-2. J Thromb Thrombolysis. 2020. PMID: 31919736
-
Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.Korean J Intern Med. 2017 Sep;32(5):769-779. doi: 10.3904/kjim.2016.391. Epub 2017 Aug 22. Korean J Intern Med. 2017. PMID: 28823143 Free PMC article. Review.
References
-
- Risk factors and long term clinical outcomes of second generation drug-eluting stent thrombosis, Insights From the REAL-ST Registry. Kuramitsu S, Ohya M, Shinozaki T, et al. Circ Cardiovasc Interv. 2019;12:0. - PubMed
-
- Stent thrombosis: a clinical perspective. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. JACC Cardiovasc Interv. 2014;7:1081–1092. - PubMed
-
- Drug-eluting stent thrombosis: current and future perspectives. Kuramitsu S, Sonoda S, Ando K, et al. Cardiovasc Interv Ther. 2021;36:158–168. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous